unknown
Stage
2019
Founded
2
Investors
About
Araris Biotech AG is a Swiss biotech spin-off from the Paul Scherrer Institute and ETH Zurich that develops proprietary peptide linker technology for antibody-drug conjugates (ADCs). Its platform enables stable, homogeneous attachment of cytotoxic payloads to antibodies to create targeted cancer therapies.
Explore Araris Biotech AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.